Onkologie 2020: 14(Suppl.C): 13-17 | DOI: 10.36290/xon.2020.050

Adrese efect of chemotherapy

Veronika Novotná, Denisa Pohanková, Igor Sirák, Jiří Petera
Klinika onkologie a radioterapie, FN Hradec Králové

Background: Chemotherapy is an important modality used in treating cancer diseases. Strictly speaking, the term chemotherapy refers to treatment with cytostatic drugs. This treatment is associated with a number of adverse effects that, more or less, can currently be managed and prevented. The most common adverse effects include fatigue, nausea and vomiting, hair loss, diarrhoea and constipation, blood count alterations such as anaemia, neutropenia, thrombocytopenia and associated infections, fever, or bleeding. Many side effects of chemotherapy occur in patients within one or several days of chemotherapy administration, after patients have returned home. Patients and their families should be informed on what side effects can be expected with particular types of chemotherapy, and should obtain basic information on how to manage these adverse effects. Of major importance for patients is the information on when they should seek medical attention and where to turn for help when not certain how to manage a health problem that has occurred. Therefore, it is necessary to acquaint patients with possible adverse effects and the ways of treating and preventing them already in the office prior to chemotherapy administration. Purpose: The review article discusses chemotherapy adverse effects, their management and possible prophylaxis.

Conclusion: Nowadays, not only the treatment of cancer disease itself, but also the quality of life of the patient treated for the disease are both very important. Hence, adequate attention has to be paid to adverse effects that may occur as a result of treatment, as well as to the use of prophylaxis that is an equally important part of patient care.

Keywords: adverse effects, prophylaxis, chemotherapy.

Published: June 2, 2020  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Novotná V, Pohanková D, Sirák I, Petera J. Adrese efect of chemotherapy. Onkologie. 2020;14(Suppl.C):13-17. doi: 10.36290/xon.2020.050.
Download citation

References

  1. Koeller JM, Aapo MS,Gralla RJ, et al. Antiemetic guidelines: creating a more practical treatment approach. Suportive Care in Cancer 2002; 10: 519-522. Go to original source... Go to PubMed...
  2. Jordan K, Sippel Ch, Schmoll HJ. Guidelines for Antiemetic Treatment of Chemotherapy-Induced Nausea and Vomiting: Past, Present, and Future Recommendations. Oncologist. 2007; 12(9): 1143-50. Go to original source... Go to PubMed...
  3. Kris MG, Hesketh PJ, Somerfield MR, et al. American Society of Clinical Oncology guideline for antiemetics in oncology: Update 2006. J Clin Oncol 2006; 24: 2932-2947. Go to original source...
  4. Roila F, Hesketh PJ, Herrstedt J, et al. Antiemetic Subcommittee of the Multinational Association of Supportive Care in Cancer. Prevention of chemotherapy - and radiotherapy-induced emesis: Results of the 2004 Perugia International Antiemetic Consensus Conference. Ann Oncol 2006; 17: 20 -28. Go to original source... Go to PubMed...
  5. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Antiemesis,V.1.2007.Available at http://www.nccn.org/ professionals/physician_gls/PDF/antiemesis.pdf. Accessed August 3, 2007.
  6. Aapro MS, Molassiotis A, Olver I. Anticipatory nausea and vomiting. Support Care Cancer 2005; 13: 117-121. Go to original source... Go to PubMed...
  7. Roila F, Donati D, Tamberi S, et al. Delayed emesis: Incidence, pattern, prognostic factors and optimal treatment. Support Care Cancer 2002; 10: 88 -95. Go to original source... Go to PubMed...
  8. Adam Z, Krejčí M, Vorlíček J, et al. Obecná onkologie. Praha: Galén, 2011: 374 s.
  9. Jordan K, Hinke A, Grothey A, et al. A meta-analysis comparing the efficacy of four 5-HT3-receptor antagonists for acute chemotherapy-induced emesis. Support Care Cancer. 2007; 15(9): 1023-33. Go to original source... Go to PubMed...
  10. Eisenberg P, Figueroa-Vadillo J, Zamora R, et al. Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist: Results of a phase III, single-dose trial versus dolasetron. Cancer 2003; 98: 2473-2482. Go to original source...
  11. Grunberg SM. Antiemetic activity of corticosteroids in patients receiving cancer chemotherapy: Dosing, efficacy, and tolerability analysis. Ann Oncol 2007; 18: 233-240. Go to original source...
  12. Hesketh PJ, Grunberg SM, Gralla RJ, et al. The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: A multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin the Aprepitant Protocol 052 Study Group. J Clin Oncol 2003; 21: 4112- 4119. Go to original source...
  13. Moreno I, Rosell R, Abad A, et al. Comparison of three protracted antiemetic regimens for the control of delayed emesis in cisplatin-treated patients. Eur J Cancer 1992; 28A: 1344-1347. Go to original source... Go to PubMed...
  14. Andreyev J, Ross P, Donnellan C, et al. Guidance on the management of diarrhoea during cancer chemotherapy. Lancet Oncol 2014; 15: e447. Go to original source... Go to PubMed...
  15. Krishnamurti S, Macaron C, Drews R, et al. Management of acute chemotherapy-related diarrhea, Up to date, 2019, https://www.uptodate.com/contents/management-of-acute-chemotherapy-related-diarrhea/print.
  16. O'Brien BE, Kaklamani VG, Benson AB 3rd. The assessment and management of cancer treatment-related diarrhea. Clin Colorectal Cancer 2005; 4: 375. Go to original source... Go to PubMed...
  17. Andreyev J, Ross P, Donnellan C, Lennan E, Leonard P, Waters C, Wedlake L, Bridgewater J, Glynne-Jones R, Allum W, Chau I, Wilson R, Ferry D. Guidance on the management of diarrhoea during cancer chemotherapy. Lancet Oncol. 2014; 15(10): e447-60. Go to original source... Go to PubMed...
  18. Richardson G, Dobish R. Chemotherapy induced diarrhea. Journal of Oncology Pharmacy Practice, 2007; 13(4): 181-198. Go to original source... Go to PubMed...
  19. Benson A, Ajani JA, Catalano RB, et al. Recommended Guidelines for the Treatment of Cancer Treatment-Induced Diarrhea. Journal of Clinical Oncology 2004; 22(14): 2918-2926. Go to original source...
  20. Shaw C, Taylor L. Treatment-related diarrhea in patients with cancer. Clin J Oncol Nurs. 2012; 16(4): 413-417. Go to original source... Go to PubMed...
  21. Prichard D, Norton C, Bharucha AE. Management of opioid-induced constipation. Br J Nurs. 2016; 25(10): S4-5, S8-11. Go to original source...
  22. Gibson RJ, Keefe DM. Cancer chemotherapy-induced diarrhoea and constipation: mechanisms of damage and prevention strategies. Supp Care Cancer. 2006; 14: 890-900. Go to original source... Go to PubMed...
  23. Ghobrial IM, Rajkumar SV. Management of thalidomide toxicity. J Support Oncol. 2003; 1(3): 194-205. Go to PubMed...
  24. Pujol JL, Viens P, Rebattu P, Laurie SA, Feld R, Deneulin A, Fandi A . Gefitinib (IRESSA) with vinorelbine or vinorelbine/cisplatin for chemotherapy-naive non-small cell lung cancer patients. J Thorac Oncol. 2006; 1(5): 417-24. Go to original source... Go to PubMed...
  25. Stojanovska V, Sakkal S, Nurgali K. Platinum-based chemotherapy: gastrointestinal immunomodulation and enteric nervous system toxicity. Am J Physiol Gastrointest Liver Physiol. 2015; 308(4): G223-232. Go to original source... Go to PubMed...
  26. Gonzalez CE, Halm JK. "Constipation in cancer patients," in Oncologic Emergency Medicine eds Todd K. H., Thomas C. R. Jr. 2016 (Switzerland: Springer International Publishing; 327-332. Go to original source...
  27. Gatti A, Sabato AF. Management of opioid-induced constipation in cancer patients: focus on methylnaltrexone. Clin Drug Investig. 2012; 32(5): 293-301. Go to original source... Go to PubMed...
  28. Deibert P, Xander C, Blum HE, et al. Methylnaltrexone: the evidence for its use in the management of opioid-induced constipation. Core Evid 2010; 4: 247-58. Go to original source... Go to PubMed...
  29. Candy B, Jones L, Vickerstaff V, Larkin PJ, Stone P. Cochrane. Mu-opioid antagonists for opioid-induced bowel dysfunction in people with cancer and people receiving palliative care. Database Syst Rev. 2018; 6: CD006332 Go to original source... Go to PubMed...
  30. Mancini I, Bruera E. Constipation in advanced cancer patients. Support Care Cancer. 1998; 6(4): 356-364. Go to original source... Go to PubMed...
  31. Wei D, Heus P, van de Wetering FT, et al. Probiotics for the prevention or treatment of chemotherapy - or radiotherapy-related diarrhoea in people with cancer. Cochrane Database Syst Rev. 2018; 8(8). Go to original source... Go to PubMed...
  32. Lacouture M, Sibaud V. Toxic Side Effects of Targeted Therapies and Immunotherapies Affecting the Skin, Oral Mucosa, Hair, and Nails. Am J Clin Dermatol. 2018; 19(Suppl. 1): 31-39. Go to original source...
  33. Hsu YH, Hung HW, Chen SC. The Effectiveness of Cooling Packaging Care in Relieving Chemotherapy-Induced Skin Toxicity Reactions in Cancer Patients Receiving Chemotherapy: A Systematic Review. Hu Li Za Zhi. 2017; 64(4): 63-70. Go to PubMed...
  34. Nangia J, Wang T, Osborne C, et al. Effect of a scalp cooling device on alopecia in women undergoing chemotherapy for breast cancer: the SCALP randomized clinical trial. JAMA. 2017; 317(6): 596-605. Go to original source... Go to PubMed...
  35. Rugo HS, Klein P, Melin SA, et al. Effect of a scalp cooling device on alopecia following chemotherapy for early-stage breast cancer. JAMA. 2017; 317(6): 606-614. Go to original source... Go to PubMed...
  36. Young A, Arif A. The use of scalp cooling for chemotherapy-induced hair loss. Br J Nurs. 2016; 25(10): S22, S24-7. Go to original source... Go to PubMed...
  37. Robert C, Sibaud V, Mateus C, Verschoore M, Charles C, Lanoy E, Baran R. Nail toxicities induced by systemic anticancer treatments. Lancet Oncol. 2015; 16(4): e181-9. Go to original source... Go to PubMed...
  38. Hackbarth M, Haas N, Fotopoulou C, Lichtenegger W, Sehouli J. Chemotherapy-induced dermatological toxicity: frequencies and impact on quality of life in women's cancers. Results of a prospective study. Support Care Cancer. 2008; 16: 267-273. Go to original source... Go to PubMed...
  39. Lacouture M, Sibaud V. Toxic Side Effects of Targeted Therapies and Immunotherapies Affecting the Skin, Oral Mucosa, Hair, and Nails. Am J Clin Dermatol. 2018 Nov; 19(Suppl 1): 31-39. Go to original source...
  40. DeHaven C. Chemotherapy and radiotherapy effects on the skin. Plast Surg Nurs. 2014; 34(4): 192-5. Go to original source... Go to PubMed...
  41. Kang D, Kim IR, Im YH, Park YH, Ahn JS, Lee JE, Nam SJ, Park H, Kim E, Lee HK, Lee DY, Cho J. Quantitative changes in skin composition parameters due to chemotherapy in breast cancer patients: a cohort study. Breast Cancer Res Treat. 2015; 152(3): 675-682. Go to original source... Go to PubMed...
  42. Sibaud V, Lebœuf NR, Roche N, et al. Dermatological adverse events with taxane chemotherapy. Eur J Dermatol. 2016; 26(5): 427-443. Go to original source...
  43. Lee C, Gianos M, Klaustermeyer WB. Diagnosis and management of hypersensitivity reactions related to common cancer chemotherapy agents. Ann Allergy Asthma Immunol. 2009; 102: 179-187. Go to original source... Go to PubMed...
  44. Castells M, Sancho-Serra MC, Simarro M. Hypersensitivity to antineoplastic agents: mechanisms and treatment with rapid desensitization. Cancer Immunol Immunother. 2012; 61: 1575-1584. Go to original source...
  45. Rowinsky EK, Donehower RC. Paclitaxel (taxol) N Engl J Med. 1995; 332: 1004-1014. Go to original source...
  46. Trudeau ME. Docetaxel (Taxotere): an overview of first-line monotherapy. Semin Oncol. 1995; 22: 17-21.
  47. Schrijvers D, Wanders J, Dirix L, et al. Coping with toxicities of docetaxel Taxotere. Ann Oncol. 1993; 4: 610-611. Go to original source...
  48. Lou Y, Wang Q, Zheng J, et. Al. Possible Pathways of Capecitabine-Induced Hand-Foot Syndrome. Chem Res Toxicol. 2016; 29(10): 1591-1601. Go to original source... Go to PubMed...
  49. Huang MD, Fuss H, Lademann J, Florek S, Patzelt A, Meinke MC, Jung S. Detection of capecitabine (Xeloda®) on the skin surface after oral administration. J Biomed Opt. 2016; 21(4): 47002. Go to original source... Go to PubMed...
  50. Kubicka-Wołkowska J, Kędzierska M, Lisik-Habib M, Potemski P. Skin toxicity in a patient with ovarian cancer treated with pegylated liposomal doxorubicin: A case report and review of the literature. Oncol Lett. 2016; 12(6): 5332-5334. Go to original source... Go to PubMed...
  51. Nowara E, Huszno J. Skin toxicity after palliative chemotherapy containing pegylated liposomal doxorubicin for ovarian cancer patients. Ann Palliat Med. 2013; 2(2): 71-75.
  52. Verstappen CC, Heimans JJ, Hoekman K, Postma TJ. Neurotoxic complications of chemotherapy in patients with cancer. Drugs 2003; 63(15): 1549-1563. Go to original source... Go to PubMed...
  53. Tao JJ, Visvanathan K, Wolff AC. Long term side effects of adjuvant chemotherapy in patients with early breast cancer. The Breast 2015; 24: S149-S153. Go to original source... Go to PubMed...
  54. Hershman DL, Lacchetti C, Dworkin RH, et al. Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. Journal of Clinical Oncology, 2014; 32(18): 1941-1967. Go to original source...
  55. Beijers AJ, Jongen JL, Vreugdenhil G. Chemotherapy-induced neurotoxicity: the value of neuroprotective strategies. Neth J Med, 2012; 70(1): 18-25.
  56. Park SB, Goldstein D, Krishnan AV, et al. Chemotherapy induced peripheral neurotoxicity: a critical analysis. CA: a cancer journal for clinicians 2013; 63(6): 419-437. Go to original source... Go to PubMed...
  57. Rapoport BL, Aapro M, Paesmans M, et al. Febrile neutropenia (FN) occurrence outside of clinical trials: occurrence and predictive factors in adult patients treated with chemotherapy and an expected moderate FN risk. Rationale and design of a real-world prospective, observational, multinational study. BMC cancer 2018; 18(1): 917. Go to original source... Go to PubMed...
  58. Groopman JE et al. Chemotherapy-induced anemia in adults: incidence and treatment. Journal of the National Cancer Institute 1999; 91(19): 1616-1634. Go to original source... Go to PubMed...
  59. Rodgers GM, Becker PS, Blinder M, et al. Cancer-and chemotherapy-induced anemia. Journal of the National Comprehensive Cancer Network 2012; 10(5): 628-653. Go to original source... Go to PubMed...
  60. Kayl AE et al. Side-effects of chemotherapy and quality of life in ovarian and breast cancer patients. Current Opinion in Obstetrics and Gynecology 2006, 18(1): 24-28. Go to original source...
  61. Taplitz RA, Kennedy EB, Bow EJ, et al. Outpatient management of fever and neutropenia in adults treated for malignancy: American Society of Clinical Oncology and Infectious Diseases Society of America clinical practice guideline update. J Clin Oncol 2018; 36(14): 1443-1453. Go to original source... Go to PubMed...
  62. de Naurois J, Novitzky-Basso I, Gill MJ, et al. Management of febrile neutropenia: ESMO clinical practice guidelines. Annals of Oncology 2010; 21(Suppl. 5): v252-v256. Go to original source... Go to PubMed...
  63. Tesařová P. Účinnost a bezpečnost přípravku Zarzio® potvrzují výsledky klinických studií i praktické zkušenosti lékařů. Klin Farmakol Farm 2014; 28(1): 37-38.
  64. Aapro M, Boccia R, Leonard R, et al. Refining the role of pegfilgrastim (a long-acting G-CSF) for prevention of chemotherapy-induced febrile neutropenia: consensus guidance recommendations. Supportive Care in Cancer 2017, 25(11): 3295-3304. Go to original source... Go to PubMed...
  65. Zavoral M, Grega T, Suchánek Š. Komplikace léčby kolorektálního karcinomu. Onkologie 2016; 10(1): 41-47. Go to original source...
  66. Elting LS, Rubenstein EB, Martin CG, et al. Incidence, cost, and outcomes of bleeding and chemotherapy dose modification among solid tumor patients with chemotherapy-induced thrombocytopenia. Journal of Clinical Oncology 2001; 19(4): 1137-1146. Go to original source...




Oncology

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.